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Abstract
Background: MECP2, the gene mutated in the majority of Rett syndrome cases, is a transcriptional regulator that
can activate or repress transcription. Although the transcription regulatory function of MECP2 has been known for
over a decade, it remains unclear how transcriptional dysregulation leads to the neurodevelopmental disorder.
Notably, little convergence was previously observed between the genes abnormally expressed in the brain of Rett
syndrome mouse models and those identified in human studies.
Methods: Here we carried out a comprehensive transcriptome analysis of human brain tissue from Rett syndrome
brain using both RNA-seq and microarrays.
Results: We identified over two hundred differentially expressed genes, and identified the complement C1Q
complex genes (C1QA, C1QB and C1QC) as a point of convergence between gene expression changes in human
and mouse Rett syndrome brain.
Conclusions: The results of our study support a role for alterations in the expression level of C1Q complex genes in
RTT pathogenesis.
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Background
Rett syndrome (RTT) is an X-linked neurodevelopmen-
tal disorder primarily affecting girls at a frequency of 1/
10,000 live female births. The core manifestations of
RTT include intellectual disability, intractable seizures,
spasticity and stereotypic hand movements [1]. More
than 95 % of classic RTT cases are caused by sporadic
mutations in the gene encoding methyl-CpG binding
protein 2 (MECP2) [2].
MECP2 encodes a nuclear protein, which belongs to
the methyl-CpG binding protein family and comprises
several distinct domains (Fig. 1): a methyl-binding
domain (MBD), intervening domain (ID), transcriptional
repression domain (TRD), and C-terminal domain
(CTD) (Hendrich and Bird, 1998). MECP2 binds with
high affinity to mCG dinucleotides, and it has been
recently shown to also bind mCA dinucleotides [3]. Al-
though present in most somatic cells, MECP2 expression
is most abundant in the brain, with a high ratio of neur-
onal to glial expression levels [4].
How MECP2 dysfunction leads to the RTT phenotype
remains unclear, despite extensive work on multiple
mouse models that partially recapitulate the neurological
abnormalities of RTT [1]. Gene expression studies of
MECP2 transgenic and knockout mice have shown that
MECP2 both activates and represses transcription [5, 6]
in the mouse brain. While initial studies pointed out to
a transcriptional repressor role of MECP2 [7, 8], involv-
ing recruitment of NCoR, HDAC3 and Sin3a, more
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recent data have uncovered an important role of MECP2
as a transcriptional activator [5]. Remarkably, MECP2’s
abundance in neuronal nuclei is similar to that of the
histone octamer, and thus MECP2 binds globally across
the methylated genome [4].
Given the transcriptional regulatory role of MECP2,
the underlying mechanism of the RTT phenotype likely
results from the dysregulation of MECP2 target genes.
Therefore, identifying genes dysregulated in human RTT
brain could provide important clues into the mechanism
of the disease. However, limited data is available on tran-
scriptome changes in human RTT brain. Previous post-
mortem brain studies using microarray platforms either
failed to identify genes that passed statistical significance
criteria after false discovery rate correction or lacked
age-matched controls [9–11], and thus little consensus
was observed between distinct human studies or be-
tween human and mouse data.
Here we carried out the first RNA-seq analysis of brain
tissue from RTT patients, and identified several hundreds
of differentially expressed genes. We also found a signifi-
cant overlap between genes downregulated in Rett brain
samples and genes activated by MECP2 in mouse models,
which included genes involved in the complement
cascade.
Results and discussion
To investigate genome-wide transcriptome changes in
human RTT brain, we obtained postmortem tissue
from four RTT cases and four age-, sex-, and ethni-
city- matched controls (Methods). For each individual
brain, we obtained tissue samples from both frontal
and temporal cortex (Fig. 1). After quality control as-
sessment of RNA samples two RTT and two control
samples were eliminated from further analyses due to
low RNA quality (see Methods). The remaining samples,
include three Rett cases with the following MECP2 muta-
tions (Fig. 1a): R1 carries a splice site mutation at the
intron3-exon4 junction (c.378-2 A >G), while R2 and R3
carry exon4 mutations: c.763 C > T (p. 255 R > X; tran-
scriptional repression domain) and c.451 G > T (p.151
D > Y; C-terminal domain) respectively. Despite the dis-
tinct mutations, the clinical picture was very similar for




Fig. 1 Outline of study design. a Localization of MECP2 mutations for the three Rett syndrome patients included in this study. Boxes represent
MECP2 exons, and the different colors display distinct protein domains. NTD: N-terminal domain, MBD-methyl binding domain, ID-intervening
domain, TRD- transcriptional repression domain, CTD- C-terminal domain. Yellow line- nuclear localization signal. b Schematic representation of
microarray and RNA-seq data generated for the 3 Rett syndrome cases and 4 controls. F-frontal cortex, T-temporal cortex. c MECP2 expression
levels measured by RNA-seq. Y-axis displays normalized RNA-seq counts. No statistically significant difference was observed between Rett
syndrome cases and controls
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secondary generalised epilepsy and kyphoscoliosis; R4516
was diagnosed with RTT and epilepsy with complex par-
tial seizures; R1815 was diagnosed with RTT, complex
partial seizures and scoliosis.
For microarray analyses, each RNA sample was ana-
lyzed separately (Fig. 1b, Methods), while for RNA-seq,
due to limited amounts of RNA, frontal and temporal
samples from the same individual were pooled as shown
in Fig. 1b. We obtained an average of 62 million sequen-
cing reads per sample, a high sequencing depth that
allowed us to detect lowly expressed transcripts.
Since dissected tissue consists of a mixture of neuronal
and glial cells, the results of gene expression analyses
could potentially be skewed by differences in cell-type
composition across samples. This issue, although im-
portant in all transcriptome studies, is particularly im-
portant in studies with a small number of samples.
However, the potentially confounding effect of cellular
composition is rarely addressed due to the difficulty of
obtaining good quality RNA from postmortem tissues
after laser-microdissection or cell sorting. Thus we used
an in silico decomposition method [12] to estimate the
proportion of neurons and astrocytes in each dissected
tissue sample, based on the microarray expression pro-
files and neuronal and astrocyte cell markers [13]
(Methods). We found that although the proportion of
neurons showed only minor variations across samples
(Fig. 2a, Additional file 1: Table S1, range: 43 % to 60 %,
p = 0.06, two-tailed t-test), the differences in cell type
composition affected the clustering of expression profiles
(Fig. 2b). The RTT samples that were more similar to
controls in terms of cell composition (R1815) clustered
with controls, while the rest of RTT samples formed a
distinct group (Fig. 2b). To address this issue, we used a
normalization method proposed for eliminating un-
wanted variation, such as experimental co-variates, from
transcriptome data (Remove Unwanted Variation (RUV)
normalization [14, 15], Methods). RUV estimates a param-
eter of unwanted variation in the data, i.e. variation not re-
lated to the case–control differences, and uses this
parameter as covariate in the generalized linear model
applied for differential expression (DE) analysis. After
applying RUV normalization to both the RNA-seq and
microarray data, we found that sample clustering no lon-
ger depended on cell-type composition (Fig. 2).
We next analyzed the RNA-seq data to identify genes
differentially expressed between RTT samples and con-
trols (Methods). We found that 244 genes (including 14
non-coding RNAs) showed significant expression
changes between RTT samples and controls (Fig. 3, FDR
< 0.05, Methods), of which 151 were down-regulated and
93 were up-regulated in Rett brain samples.
The use of two independent transcriptome analysis
methods (RNA-seq and microarrays), with distinct
chemistries, allowed us to assess the technical validation
rate of the results on a genome-wide scale, rather than
assessing a limited number of genes by a low-throughput
method (such as qRT-PCR). Of the 244 differentially
expressed genes, 174 were detected on the microarray
platform, and 73 % of these were significantly differentially
expressed based on the microarray data (FDR < 0.05, see
Methods), with the same directionality of expression
changes as identified in the RNA-seq data (Additional file
2: Table S2), indicating an appropriate technical validation
rate [16, 17].
Given the limited availability of human brain tissue
from Rett Synrome patients, we sought to use data from
RTT mouse models to assess our results in an independ-
ent dataset. To this end, we compared our DE genes
with those observed in RTT knock-out and transgenic
mice [6]. Ben-Shachar et al.[6] identified genes with con-
sistent expression changes in the cerebellum of MECP2
transgenic and knock-out mice (i.e. significant changes
in both mouse models, with opposite directionality). Of
the 270 genes identified as activated or repressed by
MECP2 in mouse, and passing the detection threshold
in our data, 13 genes were also significantly differentially
expressed in human RTT samples (Table 1), with the
same directionality as in the knock-out mice. These re-
sults indicated a significant overlap between the human
and mouse differentially expressed genes (p = 1.29E-5,
hypergeometric test; see Methods), despite the assess-
ment of distinct brain regions. Remarkably, all three
genes encoding subunits of the complement C1Q com-
plex (C1QA, C1QB, C1QC) were downregulated in
human RTT samples and in MECP2 knock-out mice,
and upregulated in MECP2 transgenic mice, strongly
suggesting that the expression of these genes is regulated
by MECP2.
Gene ontology and pathway enrichment analyses
(Methods) of down-regulated DE genes showed a signifi-
cant overrepresentation of genes implicated in immune
responses, and the complement cascade in particular
(Fig. 4a), while up-regulated genes showed no significant
functional enrichment. Notably, in addition to the C1Q
complex genes, several other genes that belong to the
REACTOME complement cascade pathway (C3, TGFBR2,
CX3CR1 and TYROBP) also showed reduced expression
in RTT brain (Fig. 4b).
Among the top 10 downregulated genes, two were
non-coding RNAs specifically expressed in human
brain and testis: RP11-178 F10.3 and RP11-122 F24.1
(-Additional file 3: Figure S1). Their functions are yet
uncharacterized, and our data highlights them as rele-
vant for further investigation.
Since a recent study reported that MECP2 primarily
represses long genes in the human brain, we assessed
the dependency of gene expression changes (log2 fold
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Fig. 2 RUV normalization corrects the effects of cellular composition on gene expression data. a Proportion of neuronal cells estimated for
each sample based on microarray expression data. b Principal component plots of microarray expression data before (left) and after (right) RUV
normalization. c Principal component plots of RNA-seq expression data before (left) and after (right) RUV normalization
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change) on gene length. We did not observe a significant
correlation between gene expression changes and gene
length (r2 = -0.02, Additional file 4: Figure S2). Although
the top three longest genes were upregulated in RTT brain
(Additional file 4: Figure S2), it is difficult to conclude that
this observation reflects a general phenomenon of length-
dependent transcriptional repression.
We were next interested to know how genes downreg-
ulated in RTT brains varied in expression in the normal
human brain during fetal and postnatal development.
Since the onset of RTT occurs around two years of age,
after an initial period of normal development, we hy-
pothesized that MECP2 transcriptional targets might
play a particularly important role during this develop-
mental time period.
To this end, we used transcriptome data from a recent
study [18] of gene expression variation in over 200 hu-
man prefrontal cortex samples, including 71 samples
from fetal and postnatal (<10 years) brains. We assessed
the correlation of gene expression with age for all genes
detected in our RNA-seq experiment and present in the
Colantuoni et al. [18] dataset. As previously reported,
the fetal to postnatal transition is associated with major
gene expression changes, as most genes undergo either
an increase or a decrease in expression during this de-
velopmental period. Interestingly, the genes differentially
expressed in RTT brain showed primarily an increase in
expression levels at the fetal to post-natal transition, a
significant shift from the bi-modal distribution of all
genes in the dataset (p < 0.05, Kolmogorov Smirnov test).
a)
b)
Fig. 3 Differentially expression analysis. a Number of differentially expressed genes. b Scatterplot of log2 fold changes in Rett syndrome samples
relative to controls, as detected by RNA-seq (X-axis) and microarrays (Y-axis). All genes identified as differentially expressed genes are displayed,
with each gene represented by a dot. Grey dots- genes not detected by microarrays, blue dots- genes that did not reach statistical significance
for differential expression based on the microarray data, red dots- genes detected as differentially expressed by both RNA-seq and microarrays
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By stratifying the genes into up- and down-regulated,
we found that the increase in gene expression at the
fetal-to-postnatal transition primarily reflected the be-
havior of downregulated genes (Fig. 5). Thus genes
downregulated in RTT brain increase in expression in
normal postnatal brain, suggesting that they may play
a functional role during this developmental period.
Our study is the first RNA-seq analysis of post-
mortem brain samples from RTT cases and age-, gender-
and ethnicity-matched controls. By careful consideration
of experimental co-variates such as cellular composition
of brain tissue samples, and effective normalization of
the data, we were able to detect several hundreds of dif-
ferentially expressed genes, and observe significant con-
vergence with gene expression changes previously
reported in RTT mouse models.
Our data points out a transcriptional deficit of genes
encoding components of the C1Q complement complex,
as well as several other genes implicated in the comple-
ment pathway: C3, TGFBR2, CX3CR1 and TYROBP.
C1Q complex genes are expressed in the brain primar-
ily in microglia, at low levels in resting state, and at
higher levels following microglial activation [19].
Although their role has been primarily characterized in
neuronflammation, complement proteins play diverse
roles in the brain, including a role in synaptic pruning
[20]. Interestingly, C1Q genes are expressed in neurons
in response to TGFβ receptor (TGFBR2) activation dur-
ing synaptic pruning [19]. The expression of C1Q genes
in response to TGFβ release from astrocytes leads to
activation of the complement cascade, and microglial-
dependent synaptic pruning [21].
An early transcriptome study of human RTT showed
upregulation of glial transcripts and downregulation of
neuron-specific mRNAs in post-mortem RTT brain [9].
Whether those results were influenced by the tissue
composition of brain samples remains unclear, but our
study highlights the importance of considering tissue
composition as a covariate in transcriptome analyses of
brain tissue samples. Two other studies have previously
investigated gene expression changes in RTT genome-
wide. Gibson et al [11] compared gene expression in
frontal and occipital cortex between six RTT cases and
six controls. Due to significant age differences between
the Rett and control group, 4–11 years old and 43–
52 years old respectively, this study focused on inter-
regional differences within each group. Our study on
the other hand, was not adequately powered to assess
gene expression differences between frontal and tem-
poral cortex for RTT cases and controls separately,
and thus larger datasets will be required to further
evaluate brain-region specific gene expression differ-
ences in RTT.
Conclusions
Our gene expression data is consistent with one of
three possible scenarios (a) a reduction of the total
number of microglia in RTT, (b) normal number of
resting microglia but reduced microglial activation, (c)
reduced expression of C1Q genes in neurons in RTT
brain.
It has been previously observed that microglia are
depleted in the later developmental stages of RTT
mouse brain, after an initial over-activation during
early postnatal development [22]. This observation is
consistent with our data, showing reduced expression
of C1Q complex genes in human RTT brain during
adolescence. Whether microglial activation also occurs
in the human RTT brain during early postnatal devel-
opment, is yet unclear. However, reduced dendritic
spine densities, which could result from excessive
synaptic pruning during early postnatal development,
is a feature of RTT documented both in mouse and
human brains [23].
Previous mouse studies have highlighted a potential
role of astrocytes and microglia in RTT [22, 24, 25].
Restoring MECP2 expression in astrocytes partially re-
stored the neurological phenotypes in a RTT mouse
model [25]. In addition, human iPSC-derived astrocytes
carrying RTT mutations adversely affect the morphology
and function of co-cultured wild-type neurons [24].
Moreover, it has been proposed that repopulating the
brain with wild-type microglia by irradiation followed by




FDR Log2FC Log2FC Log2FC
Mecp2 null/WT MECP2 Tg/WT
C1QA 0.002 −1.776 −0.278a 0.196
CTSS 0.018 −1.407 −0.122a 0.291a
C1QC 0.030 −1.355 −0.318a 0.195
C1QB 0.043 −1.337 −0.287a 0.38a
B3GNT5 0.019 −1.266 −0.351a 0.137
NR4A3 0.003 −0.952 −0.313a 0.122
GLRA3 0.041 −0.625 −0.288a 0.411a
AUTS2 0.027 0.572 0.274a −0.227a
FSTL4 0.046 0.723 0.311a −0.117a
ESRRG 0.001 0.960 0.226a −0.346a
CD83 0.004 1.121 0.096 −0.336a
VAV3 0.000 1.326 0.118a −0.313a
FKBP5 0.015 1.885 0.087 −0.397a
FDR, Log2FC: data from the present study (RNA-seq)
Log2FC Mecp2 null/WT, Log2FC Mecp2 Tg/WT: data From Ben-Shachar
et al. [6]
a: FDR <0.05
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bone-marrow transplantation could arrest the pathology
in a mouse model of RTT [26]. However, the latter result
could not be replicated in independent studies [27], indi-
cating that there is yet insufficient evidence to support
the use of bone marrow transplantation in RTT patients.
Taken together, the results of our study, the first
genome-wide assessment of transcriptional changes in
human RTT brain, support the notion that alterations in
the expression level of C1Q complex genes may contrib-
ute to RTT pathogenesis.
a)
b)
Fig. 4 Pathway enrichment analysis of differentially expressed genes. a Pathways overrepresented among genes downregulated in Rett
syndrome brain. Horizontal bars display the FDR corrected enrichment p-value on a –log10 scale. b Schematic display of genes downregulated in
Rett syndrome brain (green), which interact with DE genes in the complement pathway (red). Interactions are displayed based on data in the
REACTOME database (http://www.reactome.org). The graphical display has been generated using the REACTOME FI plugin for cytoscape
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Methods
Brain tissue samples
Post-mortem brain tissue from four female RTT patients
and four age-, sex- and ethnicity- matched controls
(Additional file 5: Table S3a) were obtained from the
NICHD Brain and Tissue Bank for Developmental
Disorders (http://medschool.umaryland.edu/btbank/). All
work with these samples was completed in accordance
with UNSW ethics requirements for work with hu-
man samples (project approval #HC13110). For each
brain, approximately 500 mg of frozen tissue was ob-
tained from frontal cortex (BA9 or PFC) and
Fig. 5 Transcriptional variation of Rett syndrome DE genes in the normal human brain. a Scatterplots of gene expression levels (Y-axis) versus age
(X-axis). Purple dots: fetal brain samples, dark blue dots: postnatal brain samples. Cor: Spearman correlation coefficients. Data from Colantuoni et
al. b Density plots of correlation coefficients between expression levels and age. Grey: all genes present in our dataset and the Colantuoni et al.
dataset, black: all differentially expressed genes, red: upregulated genes, blue: downregulated genes
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temporal cortex (BA21, BA22, or BA41/42). MECP2
mutation information was obtained from the NICHD
brain bank and confirmed by Sanger sequencing
(Additional file 5: Table S3a).
RNA samples
Total RNA was extracted from around 100 mg of brain
tissue using the Qiagen miRNEasy kit following the
manufacturer’s protocol, including an on-column DNase
I treatment. An additional DNase I (New England Bio-
labs) treatment was carried out in solution, in order to
eliminate any contaminating genomic DNA. Total
RNA was eluted in 40 μl RNase-free water and stored
at −80 °C. The concentration of RNA and double-
stranded DNA (dsDNA) were measured using the
Qubit® 2.0 Fluorometer (Life Technologies), and the
RNA integrity number (RIN) of each sample was
assessed using the Agilent 2100 Bioanalyzer (Agilent
Technologies). The RNA and dsDNA concentrations
and RIN values are listed in Additional file 5: Table
S3b. Only samples with RIN ≥ 5.0 were used in down-
stream microarray and qRT-PCR analysis. Four RNA
samples were excluded from further analysis due to
low RNA quality: both RNA samples from the RTT
case R4882 (R4882-F and R4882-T), aswell as the
control samples C1078-T and C1541-F.
Microarray data
Six control RNA samples and six RTT RNA samples
(Fig. 1) were analysed on Illumina HumanHT-12 v4 Ex-
pression BeadChip arrays. 500 ng of total RNA was
processed according to the manufacturer’s protocol and
hybridised at the UNSW Ramaciotti Centre for Genom-
ics. All samples were run on the same chip in order to
avoid batch effects. Microarray expression data was ana-
lysed using the R software (http://www.r-project.org), R
package ruv13 and the Bioconductor package Lumi [28].
Raw expression data was log2 transformed and normal-
ized by quantile normalization. Microarray quality
control criteria included high inter-array Pearson correl-
ation coefficients, low variance of mean inter-array cor-
relation and probe detection P values <0.05 in at least
30 % of the samples. Further, the ruv package was used
to estimate the unwanted variation in the data. As rec-
ommended for this method [14], we obtained negative
control genes by eliminating the top 5000 genes differ-
entially expressed between RTT samples and controls in
a first pass differential expression analysis. We applied
the RUV-2 function with default parameters and k = 2,
to obtain w coefficients, which were then used as covari-
ates in the differential expression (DE) analysis. The
choice k = 2 is the minimum k that effectively eliminates
the effect of cellular composition on sample clustering.
DE was carried out using limma [29], followed by
Benjamini and Hochberg (BH) correction for multiple
comparisons. Genes with FDR-corrected p-value < 0.05
were considered differentially expressed.
RNA-seq data
Strand-specific RNA-seq data was generated from six
RNA samples (Fig. 1): a pool of equal volumes of frontal
and temporal cortex RNA for each RTT brain (R1815-
pool, R4516-pool, R4852-pool) and two of the control
brains (C1078-pool, C1571-pool), as well as temporal
cortex RNA from a third control sample (C1541-T). 1–
5 μg of total RNA was depleted of ribosomal RNA using
the Epicentre Ribo-zero kit, according to the manufac-
turer’s protocol. Library preparation using the Illumina
TruSeq Stranded kit (http://www.illumina.com/produc
ts/truseq_stranded_total_rna_library_prep_kit.html) and
sequencing on an Illumina HiSeq 2500 sequencer were
carried out at the UNSW Ramaciotti Centre for Genom-
ics. Libraries were barcoded and sequenced in one lane,
thus avoiding lane effects, to obtain 100 bp paired-end
reads. An average of 60 million reads were obtained for
each sample (Additional file 6: Table S4). Sequencing
reads were trimmed to eliminate adaptor sequences
using Trimmomatic [30] aligned to the Human Genome
(hg19) using the TopHat spliced aligner [31] with default
parameters. Quality-control assessment of RNA-seq data
was carried out using the RNAseqQC software [32].
Gene-level expression quantification was carried out
using the Rsubread featureCount function with the fol-
lowing parameters: useMetaFeatures = TRUE, allowMul-
tiOverlap = FALSE, minMQS = 10, requireBothEndsMa
pped = TRUE, countChimericFragments = FALSE [33].
Genes with expression level >0.5 FPKM in at least 3 of
the 6 samples were retained for further analysis.
TMM (Trimmed Mean of M-values) normalised data
was analysed for a first pass differential expression analysis
using edgeR [34], in order to define negative control genes
as described above for microarrays. The unwanted vari-
ation coefficients (w) were then estimated using the RUVg
function [15] with default parameters and k = 1, and
further used as covariate in the differential expression ana-
lysis. Differential expression analysis was carried out using
edgeR with BH correction for multiple comparisons.
Genes with FDR-corrected p-value < 0.05 were considered
differentially expressed. The differential expression ana-
lysis results for RNA-seq and microarray data are pro-
vided in Additional file 7: Table S5 and Additional file 8:
Table S6 respectively.
Tissue composition analysis
The cellular composition of brain tissue samples was
assessed in silico, using the ssKL algorithm in CellMix R
package [12], based on quantile normalised (but not
log2 transformed) microarray expression data. Cell-type
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specific marker gene lists for neurons and astrocytes
were obtained from Cahoy et al. [13]. The estimated
proportions of astrocytes and neurons in each sample
are listed in Additional file 1: Table S1.
Gene ontology and pathway enrichment analysis
was carried out using the GOseq package [35], with
gene-length adjustment for RNA-seq data. Gene ontol-
ogy terms with BH corrected p-value < 0.05 were consid-
ered significant. Pathway enrichment analysis was
carried out using GSEA (http://www.broadinstitute.org/
gsea/index.jsp) and the Reactome pathway database
(http://www.reactome.org/). The gene ontology and
pathway enrichment results are listed in Additional file
9: Table S7 and Additional file 10: Table S8.
Comparison with mouse data
The overlap between the 244 genes identified as differ-
entially expressed in the present study (i.e. 1.3 % of the
entire dataset) and genes differentially expressed in
mouse models of RTT [6] was carried out using a hyper-
geometric test implemented in the phyper function in R.
270 genes had been identified as differentially expressed
in MECP2 knockout and transgenic mice, and were
quantified in our dataset, and 13 of those (i.e. 4.8 %)
were also identified as dysregulated in human RTT
brain, a statistically significant overlap (p = 1.29E-5).
Additional files
Additional file 1: Table S1. Tissue Composition. (XLS 6 kb)
Additional file 2: Table S2. List of Differentially Expressed Genes
(RNA-seq). (XLS 50 kb)
Additional file 3: Figure S1. Expression levels of RP11-178F10.3 and
RP11-122F24.1 across human tissues. Boxplots display expression levels
based on RNA-seq data from the GTEx Consortium. The plots were
generated using the GTEx potal online tool: http://www.gtexportal.org.
(JPG 280 kb)
Additional file 4: Figure S2. Dependence between gene expression
changes and gene length in Rett syndrome brain. Scatterplot displays
gene length on the X-axis and fold-changes in Rett syndrome samples
relative to control samples, as measured by microarrays, on the Y-axis, for
all genes in the dataset. Genes identified as significantly differentially
expressed are shown in red, while all other genes are shown in black.
(JPG 96 kb)
Additional file 5: Table S3. Brain tissue and RNA samples. (XLS 10 kb)
Additional file 6: Table S4. RNA-seq data overview. (XLS 7 kb)
Additional file 7: Table S5. Differential Expression Results, RNA-seq.
(XLS 2488 kb)
Additional file 8: Table S6. Differential Expression Results, Microarrays.
(XLS 2356 kb)
Additional file 9: Table S7. Gene Ontology Enrichment Results for
Downregulated Genes. (XLS 68 kb)
Additional file 10: Table S8. Pathway Enrichment Results for
Downregulated Genes. (XLS 12 kb)
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